Supplementary Fig. 4 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
Supplementary Fig. 4 A. Progression-free survival by PD-L1 status. B. Overall survival by PD-L1 status. Dot marks indicate censored data.
AIに質問
Like
Bookmark
Share
AIに質問
Like
Bookmark
Share
Supplementary Fig. 4 from A Phase 1/2 Multicenter Randomized Trial of Local Ablation Plus Toripalimab Versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma | Synapse